IRBM and their collaborators’ at the universities of Strasbourg and Siena have recently published a paper in the ACS Medicinal Chemistry Letters which describes their approach to the identification of a 5-dihydroxypyrimidine-6-carboxamide substructure as a privileged scaffold of a new…
IRBM’s Chief Science Officer, Carlo Toniatti is once again featured in the Medicine Maker. This time he takes us on a journey from the clinic, to academia, to industry – where he spent over two decades developing anti-cancer drugs. Carlo…
Our Chief Scientific Officer, Carlo Toniatti, has been featured in The Medicine Maker, where he explored how we can catalyse the discovery and development of oncology drugs. In the article, he discusses how to overcome the challenges in developing efficacious…
In an original research publication for the current issue of Frontiers in Neuroscience, IRBM and collaborators developed and applied novel ultrasensitive immunoassays to enable detection of synuclein and S129 phosphorylated synuclein in clinical samples. The new research demonstrated that S129…
As part of a special issue on exercise metabonomics, IRBM recently published a paper in Metabolites exploring the limits and advantages of using saliva to observe metabolic responses to physical exercise. Saliva offers a number of advantages over traditional blood…
Make sure that you take a look at the multiple papers we contributed to the Italian edition of ACS Medicinal Chemistry Letters. One of the studies included in the edition detailed the design, synthesis and evaluation of HIV-1 nucleocapsid protein…
We are pleased to have contributed multiple articles to the Italian special edition of ACS Medicinal Chemistry Letters, highlighting the world-class drug discovery research taking place at IRBM. One of our studies featured in this publication, deals with an exploratory program…
Earlier this year, we published a paper in Molecular Pharmaceutics that highlights our work with the CHDI Foundation to develop therapeutics that substantially improve the lives of those affected by Huntington’s disease. It is essential to understand the physiochemical properties…
At IRBM, we are aware that a screening campaign’s success is critically dependent on the quality and reproducibility of the assays used. Together with the NIH, academic institutions and pharmaceutical companies, we are participating in an EATRIS consortium initiative to…
In a recent publication for The Journal of Clinical Investigation, IRBM and our international collaborators report exciting findings regarding a potential treatment for Huntington’s disease. We found elevated levels of the active proteinase ADAM10 in the presence of the polyglutamine-expanded…